Biomarin Pharmaceutical SWOT and PESTLE Analysis

Strength

1. World leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes: BioMarin is well renowned for rendering innovative therapeutics to patients with life-threatening conditions. With seven products in its portfolio and a fully-integrated multinational organization in place, there is whetted focus on developing flagship best-of-the-breed therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. This target patient’s coup primarily comprises of children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. BioMarin is also the world leader in metabolic disease innovation with multiple products commercialized and a growing pipeline of product candidates to address non-diagnosed medical needs.

2. Bringing speedy innovative therapies to meet critical patient needs: Time is very crucial to patients with rare diseases, and Biomarin has therapies for them. The efficiency and speed of BioMarin’s research, development, manufacturing, and commercial efforts works at a commendable pace to exigently deliver therapies. This American biotechnology firm’s track record of developing and commercializing new treatments has been substantially faster than the industry average. CenterWatch, a leading source for global clinical trial information, has coronated BioMarin as one of the fastest drug developers in the industry. BioMarin also ranked tenth on Forbes list of innovative companies in 2015 and fourth best mid-size employer in America in 2019.

The remaining section under "Strength" in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

This section is available only in the 'Complete Report' on purchase.

Political

This section is available only in the 'Complete Report' on purchase.

Economic

This section is available only in the 'Complete Report' on purchase.

Social

This section is available only in the 'Complete Report' on purchase.

Technological

This section is available only in the 'Complete Report' on purchase.

Legal

1. Lawsuits against the employees for stealing trade secrets: Pharmaceuticals are at a high risk of its trade secrets being copied or stolen. In a lawsuit filed in federal court in San Francisco, BioMarin Pharmaceuticals claims that a former engineer who defected to one of its main competitors in the gene-therapy market stole more than 1,800 private documents pertaining to the company's manufacturing procedures. Gerardo Caraballo recently joined Sangamo Therapeutics. BioMarin asked the court to prevent him from having access to, disclosing, or using its proprietary information and to order him to pay back any money he earned through the improper use of its trade secrets. Caraballo allegedly resigned without saying where he was going while working as a senior engineer at BioMarin. A week and a half prior to resigning, according to the complaint, Caraballo downloaded its files to a USB device, which was discovered during an internal investigation. BioMarin claimed that Caraballo's alleged scheme posed a "grave threat" to its business and that the secrets would give Sangamo a "significant unfair advantage" for its own manufacturing processes.

The remaining section under "Legal" in the 'Complete Report' on purchase.

Environmental

This section is available only in the 'Complete Report' on purchase.